Vandetanib 300 mg
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Symptomatic, Aggressive, Sporadic, Unresectable, Locally
Conditions
Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Trial Timeline
Feb 17, 2014 → Jun 18, 2020
NCT ID
NCT01945762About Vandetanib 300 mg
Vandetanib 300 mg is a pre-clinical stage product being developed by Sanofi for Symptomatic, Aggressive, Sporadic, Unresectable, Locally. The current trial status is completed. This product is registered under clinical trial identifier NCT01945762. Target conditions include Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC).
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01945762 | Pre-clinical | Completed |
Competing Products
20 competing products in Symptomatic, Aggressive, Sporadic, Unresectable, Locally
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sodium hyaluronate + placebo injection | Daiichi Sankyo | Phase 3 | 77 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 41 |
| Esomeprazole + Matching placebo | AstraZeneca | Phase 3 | 77 |
| DFV890 + Placebo | Novartis | Phase 2 | 52 |
| Omalizumab + Omalizumab + Placebo | Novartis | Phase 2 | 52 |
| Pasireotide + Octreotide | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 2 | 52 |
| valsartan | Novartis | Approved | 85 |
| Atorvastatin - Cholestyramine - Sitosterol | Pfizer | Pre-clinical | 22 |
| Epoetin biosimilar | Pfizer | Pre-clinical | 22 |
| Apixaban + Standard of care | Pfizer | Phase 3 | 76 |
| Azithromycin plus chloroquine | Pfizer | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Aficamten + Placebo | Sanofi | Phase 3 | 76 |
| REGN7508 + Acetylsalicylic Acid (ASA) + Placebo | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Droxidopa capsules + Placebo capsules | Lundbeck | Approved | 82 |